Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | SVP, Chief Accounting Officer | June 01, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,902 |
Reported balance
After 2026-06-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-01 · Sale · Disposed 379 · Balance 61,902 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. F2: Includes 379 shares of common stock acquired by the Reporting Person on May 29, 2026 pursuant to an employee stock purchase program. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.
F2: Includes 379 shares of common stock acquired by the Reporting Person on May 29, 2026 pursuant to an employee stock purchase program.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 2, 2026 21:31 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 379 | $9.45 | $3,581.55 |
DisclosureSEC source: 0001628280-26-039938 · wk-form4_1780435911.xml · nonDerivative · entry 1 Sabatini Brent · CIK 0002037272 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,902 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. F2 · balance_after: Includes 379 shares of common stock acquired by the Reporting Person on May 29, 2026 pursuant to an employee stock purchase program. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:35 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,711 | $9.12 | $70,324.32 |
DisclosureSEC source: 0001628280-26-020823 · wk-form4_1774384534.xml · nonDerivative · entry 1 Sabatini Brent · CIK 0002037272 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,902 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:56 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,430 | $9.53 | $13,631.62 |
DisclosureSEC source: 0001628280-26-012396 · wk-form4_1772142963.xml · nonDerivative · entry 1 Sabatini Brent · CIK 0002037272 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,613 F1 · kind: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 00:13 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,829 | $7.45 | $13,631.17 |
DisclosureSEC source: 0001628280-26-011331 · wk-form4_1771978411.xml · nonDerivative · entry 2 Sabatini Brent · CIK 0002037272 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,043 F2 · kind: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.v Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 00:13 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001628280-26-011331 · wk-form4_1771978411.xml · derivative · entry 3 Sabatini Brent · CIK 0002037272 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-02-21 F3 · derivative.exercise_date: 25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 00:13 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011331 · wk-form4_1771978411.xml · nonDerivative · entry 1 Sabatini Brent · CIK 0002037272 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,872 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 20:38 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,530 | $7.79 | $11,918.70 |
DisclosureSEC source: 0001628280-26-008984 · wk-form4_1771447089.xml · nonDerivative · entry 1 Sabatini Brent · CIK 0002037272 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,872 F1 · kind: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 2,290 and 485 shares of common stock acquired by the Reporting Person on May 30, 2025 and November 28, 2025, respectively, pursuant to an employee stock purchase program. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 20:37 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,562 | $9.45 | $14,766.21 |
DisclosureSEC source: 0001628280-25-007696 · wk-form4_1740515835.xml · nonDerivative · entry 2 Sabatini Brent · CIK 0002037272 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,627 F2 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 20:37 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0001628280-25-007696 · wk-form4_1740515835.xml · derivative · entry 3 Sabatini Brent · CIK 0002037272 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-02-21 F3 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2026, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 20:37 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007696 · wk-form4_1740515835.xml · nonDerivative · entry 1 Sabatini Brent · CIK 0002037272 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,189 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:41 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,562 | $9.15 | $14,291.36 |
DisclosureSEC source: 0001628280-25-005864 · wk-form4_1739576505.xml · nonDerivative · entry 1 Sabatini Brent · CIK 0002037272 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,189 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. F2 · balance_after: Reflects ownership after acquisition by the reporting person on November 29, 2024 of 1,312 shares of common stock pursuant to the Issuer's employee stock purchase program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.